SCHEMBL3208293

SCHEMBL3208293

COS(=O)(=O)C(C)S(=O)(=O)OC

nearest known ligand 0.41

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
ALDH1A1 P00352 1/20 0.33
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3219114 0.82 USP2 (0.33) USP2TSHRCA1CA2CA14
SCHEMBL18212596 0.82 CA1 (0.39) CA1CA2CA9
SCHEMBL1772672 0.79
Ammonia Solution, Strong SCHEMBL10551938 0.76
Hydrogen Sulfide SCHEMBL29214421 0.76
SCHEMBL29258156 0.73
SCHEMBL6013328 0.73
SCHEMBL27766217 0.73
SCHEMBL6013343 0.73
SCHEMBL28110226 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119009196-B Lithium cobalt oxide battery, preparation method thereof and electric equipment 比亚迪股份有限公司 2025-06-17 CN disclosed
EP-3771014-B1 NONAQUEOUS ELECTROLYTE SOLUTION FOR POWER STORAGE DEVICES TOMIYAMA PURE CHEMICAL INDUSTRIES LTD (JP) 2025-03-05 EP disclosed
US-12155037-B2 Nonaqueous electrolyte solution for power storage devices TOMIYAMA PURE CHEMICAL INDUSTRIES, LTD. (JP) 2024-11-26 US disclosed
CN-119009196-A Lithium cobalt oxide battery, preparation method thereof and electric equipment 比亚迪股份有限公司 2024-11-22 CN disclosed
US-20210043973-A1 NONAQUEOUS ELECTROLYTE SOLUTION FOR POWER STORAGE DEVICES TOMIYAMA PURE CHEMICAL INDUSTRIES, LTD. (JP) 2021-02-11 US disclosed
EP-3771014-A1 NONAQUEOUS ELECTROLYTE SOLUTION FOR POWER STORAGE DEVICES Tomiyama Pure Chemical Industries, Limited (JP) 2021-01-27 EP disclosed
CN-111971841-A Nonaqueous electrolyte for electricity storage device 富山药品工业株式会社 2020-11-20 CN disclosed
US-10468729-B2 Method for producing non-aqueous electrolyte secondary battery ENVISION AESC JAPAN LTD. (JP) 2019-11-05 US disclosed
US-10270127-B2 Nonaqueous electrolyte secondary battery NISSAN MOTOR CO., LTD. (JP) 2019-04-23 US disclosed
US-20180191027-A1 NONAQUEOUS ELECTROLYTE SECONDARY BATTERY ENVISION AESC JAPAN LTD. (JP) 2018-07-05 US disclosed
US-20070154815-A1 Secondary battery NEC CORPORATION (JP) 2007-07-05 US disclosed
US-4950768-A ANTICARCINOGENIC AGENTS CRONYN MARSHALL W (US) 1990-08-21 US disclosed
EP-0168478-B1 CANCER CHEMOTHERAPEUTIC CYCLIC AND ACYCLIC DISULFONIC ESTER COMPOUNDS, METHOD OF USE THEREFOR, AND INTERMEDIATES CRONYN, Marshall W. (US) 1989-04-05 EP disclosed
EP-0168478-A4 CANCER CHEMOTHERAPEUTIC CYCLIC AND ACYCLIC DISULFONIC ESTER COMPOUNDS, METHOD OF USE THEREFOR, AND INTERMEDIATES. CRONYN MARSHALL W 1986-11-07 EP disclosed
EP-0168478-A1 CANCER CHEMOTHERAPEUTIC CYCLIC AND ACYCLIC DISULFONIC ESTER COMPOUNDS, METHOD OF USE THEREFOR, AND INTERMEDIATES. CRONYN MARSHALL W 1986-01-22 EP disclosed
WO-1985003075-A1 CANCER CHEMOTHERAPEUTIC CYCLIC AND ACYCLIC DISULFONIC ESTER COMPOUNDS, METHOD OF USE THEREFOR, AND INTERMEDIATES CRONYN MARSHALL W 1985-07-18 WO disclosed
US-4523015-A Process and nitroaminopyrimidone intermediates for histamine H2 -antagonists SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-06-11 US disclosed
EP-0004793-B1 2-NITRO AMINOPYRIMIDONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE TO PREPARE 2-AMINOPYRIMIDONE DERIVATIVES WHICH HAVE HISTAMINE H2-ANTAGONIST ACTIVITY SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1981-12-30 EP disclosed
US-4227000-A Intermediates in the process for making histamine antagonists SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1980-10-07 US disclosed
EP-0004793-A2 2-nitro aminopyrimidone derivatives, a process for their preparation and their use to prepare 2-aminopyrimidone derivatives which have histamine H2-antagonist activity SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210043973-A1 NONAQUEOUS ELECTROLYTE SOLUTION FOR POWER STORAGE DEVICES AQP1, NCS1, SLC9A1 USP2 4650/4885TSHR 4237/4885CA1 785/4885
US-12155037-B2 Nonaqueous electrolyte solution for power storage devices AQP1, NCS1, SLC9A1 USP2 4650/4885TSHR 4237/4885CA1 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.